

3-11-02
Cp 16438
RECEIVED
MAR 19 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Jan Raa et al

) Attorney Docket: CU-2140 TJK

Serial No.: 09/511,582 (CPA)

) Group Art Unit: 1643

Filed: February 23, 2000


) Examiner: Jeffery Stucker

Title: NOVEL, NON-ANTIGENIC, MUCOSAL ADJUVANT FORMULATION WHICH
MODULATES THE EFFECTS OF SUBSTANCES, INCLUDING VACCINE
ANTIGENS, IN CONTACT WITH MUCOSAL BODY SURFACES



CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with
the United States Postal Service by Express Mail No.
EL873838741US in an envelope addressed to the Hon.
Commissioner for Patents & Trademarks, Washington, D.C.
20231, on March 8, 2002


Lisa Pistorio

Date of Signature: March 8, 2002

Hon. Commissioner of Patents & Trademarks
Washington, D.C. 20231

TRANSMITTAL LETTER

Please find enclosed the following documents pertaining to the above-referenced
application:

Amendment and Request for Reconsideration


Request for 3-month Extension of term

Check in the amount of \$460.00

Certificate of Express Mail EL873838741US

Return Postcard

Respectfully submitted,



Attorney for Applicant(s)
David A. Frey
225 West Wacker Drive
Chicago, Illinois 60606
Reg. No. 43,618

Date: 3/9/02
Telephone: (312) 201-2327

RECEIVED

MAR 19 2002

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

TECH CENTER 1600/2900

In re Patent Application of:

Jan Raa et al.

Serial No. 09/511,582 (CPA)

Filing Date: February 23, 2000



Atty. Docket No. CU-2140 TJK

Group Art Unit: 1643

Examiner: Jeffery Stucker

#18/D
3/20/02
Lisa

Title: NOVEL, NON-ANTIGENIC, MUCOSAL ADJUVANT FORMULATION WHICH MODULATES THE EFFECTS OF SUBSTANCES, INCLUDING VACCINE ANTIGENS, IN CONTACT WITH MUCOSAL BODY SURFACES

Wildman, Harrold, Allen & Dixon
225 W. Wacker Dr.
Suite 3000
Chicago, IL 60606-1229
August 20, 2001

Hon. Commissioner of Patents & Trademarks
Washington, D.C. 20231

AMENDMENT AND REQUEST FOR RECONSIDERATION

Sir:

This is in response to the Official Action mailed on September 11, 2001 for which the initial term for response expired December 11, 2001. Please find attached a check in the amount of \$460.00 for a 3 month extension of time based on the small entity status of the Applicant, thus bringing the term for response to March 11, 2002.

IN THE ABSTRACT:

Please replace the existing abstract with the following new abstract:

Di The invention is related to a mucosal adjuvant comprising a branched beta-1,3-glucan that contains beta-1,3-linked side chains anchored by a beta-1,6-linkage to the beta-1,3-linked chains